Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Circulation. Author manuscript; available in PMC 2013 January 3.
Published in final edited form as:
PMCID: PMC3374869

Supervised Exercise vs Primary Stenting for Claudication Due to Aortoiliac Peripheral Artery Disease: 6-Month Outcomes from the CLEVER Study

Timothy P. Murphy, M.D., Donald E. Cutlip, M.D., Judith G. Regensteiner, Ph.D., Emile R. Mohler, M.D., David Cohen, M.D., Matthew R. Reynolds, M.D., M.Sc., Joseph M. Massaro, Ph.D., Beth A. Lewis, Ph.D., Joselyn Cerezo, M.D., Niki C. Oldenburg, Ph.D., Claudia C. Thum, M.A., Suzanne Goldberg, MSN, Michael R. Jaff, D.O., Michael W. Steffes, M.D., Anthony J. Comerota, M.D., Jonathan Ehrman, Ph.D., Diane Treat-Jacobson, R.N., Ph.D., M. Eileen Walsh, R.N., Ph.D., Tracie Collins, M.D., Dalynn T. Badenhop, Ph.D., Ulf Bronas, Ph.D., and Alan T. Hirsch, M.D., for the CLEVER Study investigators



Claudication is a common and disabling symptom of peripheral artery disease that can be treated with medication, supervised exercise or stent revascularization.


We randomly assigned 111 patients with aortoiliac peripheral artery disease to receive one of three treatments: optimal medical care [OMC], OMC plus supervised exercise [(SE], or OMC plus stent revascularization [ST]. The primary endpoint was the change in peak walking time (PWT) on a graded treadmill test at 6 months as compared with baseline. Secondary endpoints included free-living step activity, quality of life (QOL) using the Walking Impairment Questionnaire (WIQ) and Peripheral Artery Questionnaire (PAQ), and cardiovascular risk factors.


At six month follow-up, change in PWT (the primary endpoint) was greatest for SE, intermediate for ST, and least with OMC (mean change vs. baseline 5.8±4.6, 3.7±4.9, and 1.2±2.6 minutes, respectively; p<0.001 for the comparison of SE vs. OMC; p=0.02 for ST vs. OMC; and p=0.04 for SE vs. ST). Although disease-specific quality of life as assessed by the WIQ and PAQ also improved with both SE and ST compared with OMC, for most scales the extent of improvement was greater with ST than SE. Free-living step activity increased more with ST than with either SE or OMC alone (114±274 vs. 73±139 vs. −6±109 steps/hour) but these differences were not statistically significant.


Supervised exercise treatment results in superior treadmill walking performance than stent placement, even for those with aortoiliac PAD. The contrast between better walking performance for SE and better patient-reported QOL for ST warrants further study.


Claudication is the most frequent symptom of peripheral artery disease (PAD) (1), and is experienced by an estimated 2 million Americans. Claudication profoundly limits physical functioning (2;3) and results in a sedentary lifestyle (4), self-perceived ambulatory dysfunction (5) and poor health-related quality of life (6). Prior prospective randomized clinical trials have demonstrated the efficacy of cilostazol pharmacotherapy (7), supervised exercise rehabilitation (7;8) and endovascular revascularization (9;10) to improve objective measures of walking performance and quality of life in patients with claudication due to peripheral artery disease.

Although current guidelines suggest that pharmacotherapy, supervised exercise rehabilitation and lower extremity revascularization are effective therapies for patients with claudication (11), the relative benefits of these distinct strategies of care is not known, as there have been no multicenter clinical trials directly comparing these three strategies. In this context, the Institute of Medicine ranked study of the comparative effectiveness of claudication treatment strategies within the top 50 of all American health challenges (12). Although studies comparing supervised exercise with endovascular revascularization have been performed (13;14), they have not included an optimal medical therapy group, have combined patients with aortoiliac artery and femoropopliteal artery PAD, and have either shown similar exercise performance between treatment groups (13) or shown supervised exercise to be superior to revascularization (14;15).

Nonetheless, there are important differences between patients with aortoiliac (i.e., proximal) arterial stenoses and more distal disease that may limit the value of these comparisons. For example, individuals with aortoiliac PAD have more ischemic muscle mass with walking, are often more symptomatic than those with more distal obstruction (16), and might experience less improvement with exercise training. Moreover, there is considerably more experience with stent revascularization in the aortoiliac segment (17), and the results more predictable and durable than those observed in the femoropopliteal artery segment (1821). Therefore, we designed a randomized clinical trial to compare the benefits of optimal medical therapy, structured exercise, and stent revascularization on both walking outcomes and measures of QOL in patients with claudication due to aortoiliac PAD.


Study design

The CLEVER Study was an observer-blinded randomized multicenter clinical trial conducted at 22 sites in the U.S. and Canada (see Appendix). The study was approved by the institutional review boards (IRB) at all participating institutions and by the U.S. Food and Drug Administration. The study has been registered on since August 19, 2005 ( Identifier: NCT00132743). Study methods have been published(22;23).

Patient Selection

The study population consisted of individuals with symptoms of moderate to severe intermittent claudication (defined as ability to walk at least 2, but not more than 11, minutes on a graded treadmill test using the Gardner protocol) (24) and objective evidence of a hemodynamically significant aortoiliac arterial stenosis. Individuals with critical limb ischemia or who had comorbid conditions that limited their walking ability were excluded. Two treadmill tests were completed at baseline to confirm reproducibility of results; those who deviated more than 25% were excluded. Evidence of aortoiliac stenosis involving the most symptomatic limb was established by either noninvasive vascular testing (ABI <0.9, thigh-brachial index <1.1, common femoral artery systolic acceleration time >140 msec (25;26)) (N=41); duplex ultrasound (doubling of peak systolic velocity in the aortoiliac segment, combined with an ABI <0.9) (N=26); or computed tomographic angiography (N=28) or magnetic resonance angiography (N=5) confirming at least a 60% stenosis by cross-sectional imaging test, combined with Doppler ultrasound waveform analysis (showing biphasic common femoral artery waveform (26)); or catheter angiography (≥50% stenosis in the aorta or iliac arteries) (N=19). Individuals meeting symptom and testing criteria were allowed in the study without regard to extent of aortoiliac obstruction or the presence of femoropopliteal PAD, except that patients with total aortoiliac occlusion from the level of the renal arteries to the inguinal ligaments were excluded.

Baseline evaluation

Participants were evaluated at baseline and 6 months. Demographic data were collected, and anthropomorphic and physiologic variables (body mass index, waist circumference, blood pressure); atherosclerosis risk factors (lipid profile, HbA1c); and inflammatory biomarkers were also assessed (plasma fibrinogen, C-reactive protein). Participants were asked to wear pedometers during all waking hours for a seven-day period between the two baseline treadmill tests, and to log compliance. Participants completed generic (i.e., not disease-specific) and disease-specific quality of life surveys (SF-12 (27), Walking Impairment Questionnaire (5), and Peripheral Artery Questionnaire (28)).

Randomization and Interventions

This study evaluated distinct strategies of care in three treatment groups: (i) optimal medical care (OMC), (ii) supervised exercise rehabilitation (SE), and (iii) stent revascularization (ST). A fourth treatment group that combined ST and SE was dropped after enrolling 8 participants upon the recommendation of the Data Safety and Monitoring Board (DSMB) in order to enhance enrollment in treatment groups that were part of the primary endpoint. Randomization was performed using a real-time web-based randomization system in a 2:2:1 ratio (ST:SE:OMC) (half as many enrolled in OMC because the treatment effect between the other groups and OMC was assumed to be much larger than between SE and ST). Randomization was stratified by geographic region and cilostazol use at baseline.

Optimal medical care was established via active promotion of the standards established by the intersocietal 2005 ACC-AHA Guidelines for the Management of Patients with Peripheral Artery Disease in order to promote best practices for risk factor management; use of antiplatelet therapy; and use of claudication pharmacotherapy. All study participants received cilostazol (Pletal™, Otsuka America, Inc., San Francisco, CA) 100 mg by mouth twice daily as tolerated. In addition, OMC included advice about the use of home exercise and diet in the form of standardized verbal instructions as well as printed material (Krames Staywell, San Bruno, CA). Cardiovascular risk factor data were collected and feedback provided to the sites by a central risk factor committee. Risk factors were then managed directly by the local study site.

Supervised exercise consisted of 26 weeks of exercise, three times a week, for an hour at a time. Sites were trained to provide SE using a common protocol and progress of each participant was monitored by an oversight committee (23).

Stent revascularization was done to relieve all hemodynamically significant stenoses (>50% by diameter) in the aorta and iliac arteries using FDA-approved self-expanding or balloon-expandable stents. The protocol allowed for femoropopliteal endovascular revascularization to treat any additional focal lesions, but this was not done for any study participant. Intra- or post-procedure oral antiplatelet medication use was at the discretion of the operator.


Participants were called monthly to inquire about adverse events; at three months to refill their cilostazol medication; and at six months to undergo the same testing as at baseline, except that the treadmill test was performed only once at the six month outcome evaluation. Any recurrence of claudication symptoms would initiate an evaluation for significant restenosis. Pedometers were worn for seven consecutive days immediately prior to the 6 month treadmill test.


The study primary endpoint was the change from baseline to 6 months in the peak walking time (PWT) on a graded treadmill test (Gardner protocol). PWT has been considered the most objective and reliable endpoint to evaluate improvements in functional status for patients with claudication evaluated in clinical trials (29). Secondary endpoints included changes in the following parameters: claudication onset time (COT), change in community-based walking as assessed by pedometer measurements over 7 consecutive days, self-reported walking and quality of life, and biomarkers of cardiovascular disease risk.


Claudication onset time (COT) was defined as the treadmill time when calf muscle discomfort was first noticed by a study participant on the graded treadmill test. For those individuals who did not experience any claudication symptoms during follow-up testing, COT was considered to be the same as the peak walking time (PWT). Community-based step activity was measured using pedometers (Omron Healthcare Inc., Lake Forest, IL). Pedometers recorded cumulatively 7 days of step activity and required no interaction from study participants. Since the purpose was to measure unstructured walking, participants in the SE group were instructed to not wear their pedometers during supervised exercise training sessions, and steps were normalized per hour of free-living daily activity as recorded by participants. Body mass and height were measured using medical stadiometers and converted to body mass index (BMI) using the formula {BMI=mass (kg)/height (m2)}. Waist circumference was measured using a flexible tape measure under clothing on a horizontal plane at the level of the upper iliac crest. Biochemistry tests were done by the core laboratory at the University of Minnesota. Cilostazol compliance was assessed by pill counts performed at quarterly visits.

Symptoms and Quality of Life

Patient-reported symptoms, functional status, and health-related quality of life (QOL) were assessed using three validated questionnaires, each administered at baseline and 6 months. The Medical Outcomes Study 12-Item Short form survey (SF-12) was used to assess generic QOL (27). Physical and mental summary scores from the SF-12 correlate highly with those obtained from the SF-36 (27) and are scaled to a U.S. population mean of 50 and standard deviation of 10 (higher scores are better). Multiple groups have suggested minimal clinically important changes in SF-12 summary scores to be greater than 2–2.5 points, and moderate changes to be greater than 5 points (2;3).

Claudication-related symptoms and functional impairment were assessed using two questionnaires designed for and validated in patients with PAD: the Walking Impairment Questionnaire (WIQ) (5) and the Peripheral Artery Questionnaire (PAQ) (28). The WIQ grades symptom severity as well as patient ratings of their walking distance, walking speed, and ability to climb stairs on 0–100 scales, with higher scores indicating lesser symptoms and greater functional capacity. The PAQ assesses PAD-related physical limitation, symptoms, quality of life, social function and treatment satisfaction, also on 0–100 scales; higher scores are better. For the PAQ summary scale, a difference of 8 points has been proposed as clinically important (6). The minimum clinically important difference has not been established for the WIQ.

Statistical Methods

Baseline characteristics were compared using chi square for categorical variables and one-way ANOVA for continuous variables. The primary endpoint was assessed using sequential pairwise analysis of covariance adjusting for clinical site, baseline PWT, and cilostazol use (adjustments done to increase precision of the statistical comparison). The second baseline treadmill test was used for the comparison. Separate pairwise models were fit using the given two groups being compared. First, supervised exercise and stenting were each compared with optimal medical therapy with a one-sided 0.025 level of significance. Given significance of both comparisons, supervised exercise and stenting were then compared with a 2-sided 0.05 level of significance.

The secondary endpoints of change in free-living daily step activity measured by pedometer use, biomarkers, and quality of life indicators were assessed by pairwise analysis of covariance, adjusting for baseline cilostazol use and study center but with a two-sided significance level of 0.05 for each comparison without adjustment for multiple comparisons. Pedometer activity was normalized to steps per hour to account for differences in hours of pedometer use during the assessment period. All analyses were conducted according to intention-to-treat. Results are based on available data. Multiple imputation of missing primary endpoint data was also performed.

We estimated the PWT would improve by 60% in OMC, 125% in SE, and 164% for ST, based on published data (7;9;30). Given baseline mean (SD) PWT estimate of 5.0 (3.8) minutes, with 63 evaluable participants in both the ST and SE groups, or 158 participants total between ST, SE, and OMC, the study had 80% power to detect the difference between SE and ST, >99% power for ST vs. OMC comparison, and 98% power for SE vs. OMC. Allowing for 30% premature withdrawal and inclusion of an exploratory arm of ST plus SE, a sample size of 252 was planned. The sample size was adjusted to 217 after removal of the ST plus SE arm due to slow enrollment. Although the study did not meet conservative pre-specified stopping rules, recruitment was stopped early on recommendations of the DSMB due to slow enrollment after review of interim results.


Study Population

Between April 2007 and January 2011, there were 119 study participants randomized (Figure 1). The final population of 119 reflects the sample size after enrollment was terminated by the DSMB. At baseline, the study population age was 64.0±9.5 years, 61.3% were male, 53.8% were current smokers, and 23.1% had diabetes. All three groups were well-matched in terms of baseline demographics and performance variables, except for a higher prevalence of male gender and prior stroke in the SE group (Table 1). Similarly, baseline anthropomorphic, physiologic, and biochemical characteristics were also similar at baseline across the treatment groups (Table 2).

Figure 1
CONSORT diagram
Table 1
Demographic and Background Characteristics
Table 2
Baseline Physiologic, Biochemical, and Anthropomorphic Characteristics

Treatment Delivery

There were no cross-overs during the 6 month follow-up period. Of the 43 patients assigned to the SE group, 2 withdrew prior to beginning treatment, and 29 of the remaining 41 (71%) attended at least 70% of their scheduled 78 supervised exercise training sessions.

For patients assigned to the ST group, all stent procedures were technically successful. There were 19 right common iliac arteries treated, 8 right external iliac arteries, 20 left common iliac arteries, and 7 left external iliac arteries treated. One patient underwent aortic stenting and no patients underwent a concomitant femoropopliteal artery endovascular procedure. The mean lesion length was 3.9±3.4 cm, and the mean stenosis pre-procedure was 83±19%. The population was similar in terms of disease severity as other uncontrolled case series that have been published (17), with 14/37 (38%) of ST patients who received the ST treatment having total occlusions. Post-procedure the mean stenosis was 5±8%. The mean ankle-brachial index (ABI) was 0.66±0.2 at baseline and improved by 0.29±0.33 at six months. The average number of stents used per participant was 1.8±1.2. An evaluation for restenosis was not indicated by recurrent leg symptoms during follow-up in any study participant.

Adherence to cilostazol was >90% and similar across all 3 treatment groups. Similarly, there were no differences in the use of statin medications or rates of current smoking across treatment groups (see table 1).

Primary Endpoint

Compared with baseline, the primary endpoint (PWT) improved by 1.2±2.6 minutes with OMC alone, 5.8±4.6 minutes with SE, and 3.7±4.9 minutes with ST. When compared with OMC alone, SE led to a greater mean improvement in PWT by 4.6 minutes (95% CI, 2.7 to 6.5 minutes, p<0.001), whereas ST had a somewhat smaller relative improvement in PWT of 2.5 minutes (95% CI, 0.6 to 4.4 minutes, p=0.022). The direct comparison of SE vs. ST demonstrated a greater improvement in PWT with SE by a mean of 2.1 minutes (95% CI, 0.0 to 4.2 minutes, p=0.04). Similar results were observed when the analysis was repeated using non-parametric analyses (Table 3). Analyses were repeated without inclusion of individuals with a stroke history in the SE group and were similar to those for the entire cohort.

Table 3
Six Month Endpoints and Risk Factors

Secondary Endpoints

At 6 month follow-up, there were no statistically significant changes in ABI measurements compared to baseline in either the OMC and SE treatment group, whereas the resting ABI improved by ABI 0.29±0.33 in the ST group (p<0.0001) (Table 3). For COT, both SE and ST demonstrated significantly greater improvement as compared with OMC, but no significant difference was observed between ST and SE participants. Patients assigned to both SE and ST had greater increases in community-based step activity than OMC participants, but this was not statistically significant (Table 3).

Atherosclerosis risk factors demonstrated a greater improvement in HDL-cholesterol among individuals in the SE group compared with ST, and a trend for HDL-cholesterol improvement in the OMC group compared with ST patients. There was also a statistically significant greater decrease in plasma fibrinogen levels in the SE group compared with OMC (Table 3).

Symptoms and Quality of Life

The SF-12 physical summary score and disease-specific measures of symptoms, physical limitation and walking ability were low at baseline, with no differences between treatment groups (Table 4) (36). In particular, the SF-12 physical summary scores were nearly 2 standard deviations below the U.S. population average.

Table 4
Six Month Leg Symptoms and Quality of Life

At 6 months, the ST group improved more than the OMC group for every QOL measure except the SF-12 mental summary scale, which was normal at baseline, and the WIQ stair climbing scale (Table 4). SE improved more than OMC for every scale except SF-12 mental, WIQ-pain, WIQ-stair climbing, PAQ-symptom stability, and PAQ-treatment satisfaction. Compared with SE, ST was associated with significantly greater benefit across most of the disease-specific QOL measures but not for the generic scales. The difference between ST and SE for the PAQ overall summary score (14.78 points) exceeded the 8-point difference that has been considered clinically meaningful (31). At 6 months, more patients in the ST group (17/40, 42.5%) than the SE group (8/38, 21%) reported no claudication symptoms on the WIQ.

Multivariable regression analysis demonstrated a significant interaction between treatment group and PWT for the association with QOL measures [PAQ-physical limitation (p=0.025) and WIQ-distance (p=0.01)]. For the ST group, the degree of improvement in PWT was highly correlated with improvement in both the PAQ-physical limitation score as well as the WIQ distance domain (a one minute improvement in PWT leads to an average improvement in PAQ of 4.1 and in WIQ of 5.9; Pearson correlation r versus PWT is 0.65 for PAQ and 0.69 for WIQ, respectively; both p<0.001). On the other hand, for the SE group, the PWT improvement was more weakly correlated with the WIQ distance domain (a one minute improvement in PWT leads to an average improvement in WIQ of 2.0; r=0.33; p=0.05) and there was no significant correlation with the PAQ-physical limitation score (r=0.24; p=0.19). This distinction was less apparent for COT, which correlated strongly with both the PAQ-physical limitation and WIQ-distance scores (one minute improvement in COT leads to an average improvement in PAQ of 3.9 and in WIQ of 5.6; r versus COT is 0.62 for PAQ and 0.66 for WIQ, respectively; both p<0.001) with no significant interaction with treatment group (p=0.26).


Overall, there were four serious adverse events (SAE) within 30 days of the stent procedure. These included one arterial perforation managed with a stent graft without sequelae, one participant who required a transfusion (the same one who had the perforation), and 2 localized dissections noted. On follow-up there were no SAEs associated with use of supervised exercise and cilostazol was well tolerated.


This study represents the first multicenter randomized controlled trial that examines the relative benefit of SE, ST and OMC, and the first conducted exclusively on patients with aortoiliac PAD, long considered ideal for stent revascularization. The population had relatively severe PAD, with 38% of the ST group having total occlusions in the aortoiliac segment, with low ABIs, poor treadmill test performance, and poor QOL throughout all treatment groups at baseline.

Prior randomized trials comparing supervised exercise and percutaneous revascularization pooled patients with aortoiliac and femoropopliteal PAD, and have shown supervised exercise to provide superior treadmill test walking at 6 months (13;14;32;33). It has been questioned whether such studies that showed the benefits of supervised exercise vis-à-vis endovascular revascularization were generalizable to patients with aortoiliac PAD, long considered the ideal population for stent placement (13). This study shows that for a population with advanced aortoiliac PAD, changes in PWT over 6 months were greater among those who received supervised exercise therapy than those revascularized with stents.

It is noted that improvements in treadmill measures of functional status were not observed in the pedometer-derived measurements of community walking. This has been observed in other clinical trials of exercise for PAD, as use of SE has been shown to increase 6 minute walk and treadmill walking outcomes, but not pedometer-based measures of community walking. It is possible that improved leg function may, even with an associated improvement in claudication symptoms, not consistently lead to an increase in a patient's ambulatory behavior (34).

Both SE and ST demonstrated improvements in PWT and QOL. Although SE showed more improvement in PWT, considered the standard endpoint for claudication research (29), the greatest improvements in self-reported QOL were observed in the ST cohort. This study was not designed to determine the cause of differential objective PWT and subjective QOL outcomes from patients provided these distinct strategies of care. Superior treadmill-defined benefits from the SE group could be derived from the “specificity-of-training” effect or from improved cardiorespiratory fitness, as the use of SE is known to be associated with physiologic improvement in systemic and limb function. This study also did not evaluate the exact mechanism(s) by which SE improved exercise performance, which can include multiple physiologic adaptive effects and treadmill use familiarity. Eighteen month results, obtained a year after completion of treadmill training, should provide valuable additional information.

This study demonstrated adequate adherence to supervised exercise in a community treatment setting using a centrally administered program; risk factor control achieved via use of a structured patient informational program; SE and ST benefit in the context of an active claudication medication; that both SE and ST interventions were safe; and that SE is an efficacious intervention for patients with PAD in the aortoiliac segment.

In summary, these results indicate both treatments are superior to OMC and provide widened choices for all patients. The selection of the ideal treatment will depend on the patient's preference. At the very least, the CLEVER 6 month results suggests that SE is a reasonable strategy compared with stenting and that efforts be made to develop SE programs that are available and affordable to patients.


These 6-month results are relatively short-term, and the 6-month endpoint coincided with the completion of supervised exercise therapy when exercise benefits are expected to be their greatest. The longer term 18-month benefit and harm of exercise and stenting, and health economic impact of these approaches to claudication treatment is under evaluation in this study. However, in a study of a chronic disease whose treatments are directed at symptom relief, near-term outcomes are clinically relevant. The efficacy of these strategies of care for individuals with claudication due to femoropopliteal PAD anatomy is not known. However, there is much controversy surrounding methods of revascularization for the femoropopliteal segment, in contrast to the aortoiliac segment, where stent revascularization has a proven track record. Indeed, the results of this study are generalizable to those with aortoiliac PAD, a large population, with or without concomitant femoropopliteal artery PAD. Finally, the study has a smaller sample size than originally planned, partly due to slow enrollment. Slow enrollment has been a hallmark of most comparative effectiveness clinical trials, in which recruitment is typically hampered by clinician bias in favor of one treatment strategy or a reimbursement bias that is not comparable across the tested interventions.


This study demonstrates that for patients with claudication, supervised exercise provides a superior improvement in treadmill walking performance compared to both primary aortoiliac stenting and optimal medical care (home walking and cilostazol) over six months. This benefit is associated with an improvement in self-reported walking distance, an increase in HDL and decrease of fibrinogen. Secondary measures of treatment efficacy favored primary stenting, with greater improvements in self-reported physical function.


The CLEVER Study (Claudication: Exercise Vs. Endoluminal Revascularization) was sponsored mostly by the National Heart Lung and Blood Institute (grants HL77221 and HL081656), and also received financial support from Cordis/Johnson & Johnson (Warren, NJ), eV3 (Plymouth, MN), and Boston Scientific (Natick, MA). Otsuka America, Inc., (San Francisco, CA) donated cilostazol for all study participants throughout the study. Omron Healthcare Inc., Lake Forest, IL donated pedometers. Krames Staywell, San Bruno, CA, donated print materials for study participants on exercise and diet.


Timothy P. Murphy, M.D.: Research grant support - Abbott Vascular, Cordis/Johnson&Johnson, Otsuka Pharmaceuticals; consultant - Microvention/Terumo, Inc.; David Cohen, M.D.: Research grant support - Medtronic. Boston Scientific, Abbott Vascular, Medrad; consultant - Medtronic, Inc.; Matthew R. Reynolds, M.D., M.Sc. : Consultant - Medtronic, Inc.; Michael R. Jaff, D.O.: Equity - Micell, Inc., PQ Bypass; board membership - VIVA Physicians, Inc.; consulting - Becker Venture Services Group, Abbott Vascular, Cordis Corporation, Covidien/eV3, Medtronic Vascular; Diane Treat-Jacobson, R.N., Ph.D.: Research grant support - NHLBI/Exercise training for claudication: Arm ergometry versus treadmill walking study; Tracie Collins, M.D.: Data Safety Monitoring Board member for Viromed BioPharma/Synteract; Alan T. Hirsch, MD..: Research Grant Support - Cytokinetics, Viromed, Abbott Vascular; consultant - Merck, Pozen, Novartis, AstraZeneca.


The CLEVER investigators, co-authors and committee members were as follows - Principal investigators (in order of decreasing number of patients who were randomly assigned to a treatment group): T. Murphy, Rhode Island Hospital, Providence, RI; J. Ehrman, Henry Ford Hospital, Detroit, MI; V. Krishnamurthy, VA Ann Arbor, Ann Arbor, MI; J. Nadarajah, Aiyan Diabetes Center, Augusta, GA; A. T. Hirsch, University of Minnesota and Minneapolis Heart Institute Foundation, Minneapolis, MN; A. Comerota, Jobst Vascular Center, Toledo, OH; M. Lurie, Torrance Memorial Medical Center, Torrance, CA; W. Miller, Vascular Endovascular Specialists of Ohio, Mansfield, OH; O. Osinbowale, Ochsner Health Center, Metairie, LA; S. Cavalieri, Providence Medical Research Center, Spokane, WA; M. Razavi, St. Joseph Hospital, Orange, CA; R. Workman, Forsyth Medical Center, Winston-Salem, NC; R. Berry, Capital Health, Nova Scotia, Canada; E. Ratchford, Johns Hopkins, Baltimore, MD; A. Tassiopoulos, Stony Brook, NY; E. Mohler, University of Pennsylvania, Philadelphia, PA; W. Abernethy, Asheville Cardiology, Asheville, NC; J. Matsuura, Iowa Clinic, Des Moines, IA; J. Kaufman, Oregon Health Science University, Portland, OR; J. Martinez, Peripheral Vascular Associates, San Antonio, TX; M. Moursi, VA Central Arkansas, Little Rock, AR; F. Bech, VA Palo Alto, Palo Alto, CA; Co-authors: D.E. Cutlip, Beth Israel Deaconess Medical Center, Harvard Clinical Research Institute, Boston, MA; J.G. Regensteiner, University of Colorado Denver School of Medicine, Aurora, CO; E.R. Mohler III, Vascular Medicine University of Pennsylvania, Philadelphia, PA; D.J. Cohen, St. Lukes Mid America Heart Institute, Kansas, MO; M.R. Reynolds, Harvard Medical School, Harvard Clinical Research Institute, Boston, MA; E.A. Lewis, University of Minnesota School of Kinesiology, Minneapolis, MN; J.V. Cerezo, Vascular Disease Research Center, Rhode Island Hospital, RI; N.C. Oldenburg, Cardiovascular Division, University of Minnesota, Minneapolis, MN; C.C. Thum, Harvard Clinical Research Institute, Boston, MA; S.Goldberg, National Heart, Lung, Blood Institute, Bethesda, MD; M. Jaff, Massachusetts General Hospital, Boston, MA; J.K. Ehrman, Preventive Cardiology Henry Ford Hospital, Detroit, MI; D.T. Badenhop, University of Toledo Medical Center, Toledo, OH; D. Treat-Jacobson, University of Minnesota School of Nursing, Minneapolis, MN; M.E. Walsh, University of Toledo College of Nursing, Toledo, OH; T. Collins, General Internal Medicine University of Minnesota, Minneapolis, MN; M.W. Steffes, University of Minnesota Laboratory Medicine and Pathology, Minneapolis, MN; A.T. Hirsch, Vascular Medicine Program, Lillehei Heart Institute, Cardiovascular Division, University of Minnesota Medical School, Minneapolis, MN; Steering Committee: A. T. Hirsch (chair), T. P. Murphy, J. G. Regensteiner, M. Jaff, D.J. Cohen, A.J. Comerota, D.E. Cutlip, E.R. Mohler, E.A. Lewis, M.W. Steffes, S. Goldberg; Exercise Training Committee: J.G. Regensteiner (chair), E.A. Lewis, A. Ershaw, D. Treat-Jacobson, T. Collins, D.T. Badenhop, J.K. Ehrman, M.E. Walsh, U. Bronas, N.C. Oldenburg; Risk Factor Committee: Emile R. Mohler III, Mark Lurie, MD, Teresa Caulin-Glaser, MD, Yung-Wei Chi, MD, Abby Ershow, PhD; Data and Safety Monitoring Board: T.A. Pearson (chair), B.H. Annex, M. Hlatky, M.T. Hughes, M.M. Brooks, R.J. Powell, A. Roberts, J.A. Vita.

Reference List

1. Ouriel K. Peripheral arterial disease. Lancet. 2001;358:1257–1264. [PubMed]
2. Barletta G, Perna S, Sabba C, Catalano A, O'Boyle C, Brevetti G. Quality of life in patients with intermittent claudication: relationship with laboratory exercise performance. Vasc Med. 1996;1:3–7. [PubMed]
3. McDermott MM, Greenland P, Liu K, Guralnik JM, Criqui MH, Dolan NC, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA. 2001;286:1599–1606. [PubMed]
4. Sieminski DJ, Gardner AW. The relationship between free-living daily physical activity and the severity of peripheral arterial occlusive disease. Vasc Med. 1997;2:286–291. [PubMed]
5. Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg. 1996;23:104–115. [PubMed]
6. Feinglass J, McCarthy WJ, Slavensky R, Manheim LM, Martin GJ. Effect of lower extremity blood pressure on physical functioning in patients who have intermittent claudication. The Chicago Claudication Outcomes Research Group. J Vasc Surg. 1996;24:503–511. discussion 511-2. [PubMed]
7. Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for claudication. N Engl J Med. 2002;347:1941–1951. [PubMed]
8. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2000:CD000990. [PubMed]
9. Murphy TP, Soares GM, Kim HM, Ahn SH, Haas RA. Quality of life and exercise performance after aortoiliac stent placement for claudication. J Vasc Interv Radiol. 2005;16:947–953. quiz 954. [PubMed]
10. Nordanstig J, Gelin J, Hensater M, Taft C, Osterberg K, Jivegard L. Walking performance and health-related quality of life after surgical or endovascular invasive versus non-invasive treatment for intermittent claudication--a prospective randomised trial. Eur J Vasc Endovasc Surg. 2011;42:220–227. [PubMed]
11. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic. Circulation. 2006;113:e463–e654. [PubMed]
13. Perkins JM, Collin J, Creasy TS, Fletcher EW, Morris PJ. Exercise training versus angioplasty for stable claudication. Long and medium term results of a prospective, randomised trial. Eur J Vasc Endovasc Surg. 1996;11:409–413. [PubMed]
14. Spronk S, Bosch JL, den Hoed PT, Veen HF, Pattynama PM, Hunink MG. Intermittent claudication: clinical effectiveness of endovascular revascularization versus supervised hospital-based exercise training--randomized controlled trial. Radiology. 2009;250:586–595. [PubMed]
15. Murphy TP, Spronk S, de Ridder M, Lesaffre EM. Primary end-point error. Radiology. 2010;256:1011. author reply 1011-2. [PubMed]
16. Pernow B, Zetterquist S. Metabolic evaluation of the leg blood flow in claudicating patients with arterial obstructions at different levels. Scand J Clin Lab Invest. 1968;21:277–287. [PubMed]
17. Murphy TP, Ariaratnam NS, Carney WI, Jr, Marcaccio EJ, Slaiby JM, Soares GM, et al. Aortoiliac insufficiency: long-term experience with stent placement for treatment. Radiology. 2004;231:243–249. [PubMed]
18. Sapoval MR, Long AL, Raynaud AC, Beyssen BM, Fiessinger JN, Gaux JC. Femoropopliteal stent placement: long-term results. Radiology. 1992;184:833–839. [PubMed]
19. Vroegindeweij D, Vos LD, Tielbeek AV, Buth J, vd Bosch HC. Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: A comparative randomized study. Cardiovasc Intervent Radiol. 1997;20:420–425. [PubMed]
20. Laird JR. Limitations of percutaneous transluminal angioplasty and stenting for the treatment of disease of the superficial femoral and popliteal arteries. J Endovasc Ther. 2006;13(Suppl 2):II30–II40. [PubMed]
21. Schlager O, Dick P, Sabeti S, Amighi J, Mlekusch W, Minar E, et al. Long-segment SFA stenting--the dark sides: in-stent restenosis, clinical deterioration, and stent fractures. J Endovasc Ther. 2005;12:676–684. [PubMed]
22. Murphy TP, Hirsch AT, Ricotta JJ, Cutlip DE, Mohler E, Regensteiner JG, et al. The Claudication: Exercise Vs. Endoluminal Revascularization (CLEVER) study: rationale and methods. J Vasc Surg. 2008;47:1356–1363. [PMC free article] [PubMed]
23. Bronas UG, Hirsch AT, Murphy T, Badenhop D, Collins TC, Ehrman JK, et al. Design of the multicenter standardized supervised exercise training intervention for the claudication: exercise vs endoluminal revascularization (CLEVER) study. Vasc Med. 2009;14:313–321. [PubMed]
24. Gardner AW, Skinner JS, Cantwell BW, Smith LK. Progressive vs single-stage treadmill tests for evaluation of claudication. Med Sci Sports Exerc. 1991;23:402–408. [PubMed]
25. Burnham SJ, Jaques P, Burnham CB. Noninvasive detection of iliac artery stenosis in the presence of superficial femoral artery obstruction. J Vasc Surg. 1992;16:445–451. discussion 452. [PubMed]
26. Shaalan WE, French-Sherry E, Castilla M, Lozanski L, Bassiouny HS. Reliability of common femoral artery hemodynamics in assessing the severity of aortoiliac inflow disease. J Vasc Surg. 2003;37:960–969. [PubMed]
27. Ware J, Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220–233. [PubMed]
28. Spertus J, Jones P, Poler S, Rocha-Singh K. The peripheral artery questionnaire: a new disease-specific health status measure for patients with peripheral arterial disease. Am Heart J. 2004;147:301–308. [PubMed]
29. Hiatt WR, Hirsch AT, Regensteiner JG, Brass EP. Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Vascular Clinical Trialists. Circulation. 1995;92:614–621. [PubMed]
30. Regensteiner JG, Meyer TJ, Krupski WC, Cranford LS, Hiatt WR. Hospital vs home-based exercise rehabilitation for patients with peripheral arterial occlusive disease. Angiology. 1997;48:291–300. [PubMed]
31. Safley DM, House JA, Laster SB, Daniel WC, Spertus JA, Marso SP. Quantifying improvement in symptoms, functioning, and quality of life after peripheral endovascular revascularization. Circulation. 2007;115:569–575. [PubMed]
32. Creasy TS, McMillan PJ, Fletcher EWL, Collin J, Morris PJ. Is percutaneous transluminal angioplasty better than exercise for claudication?—Preliminary results from a prospective randomized trial. Eur J Vasc Surg. 1990;4(2):135–140. [PubMed]
33. Mazari FA, Gulati S, Rahman MN, Lee HL, Mehta TA, McCollum PT, Chetter IC. Early outcomes from a randomized, controlled trial of supervised exercise, angioplasty, and combined therapy in intermittent claudication. Ann Vasc Surg. 2010 Jan;24(1):69–79. Epub 2009 Sep 17. [PubMed]
34. McDermott MM, Ades P, Guralnik JM, Dyer A, Ferrucci L, Liu K, Nelson M, Lloyd-Jones D, Van Horn L, Garside D, Kibbe M, Domanchuk K, Stein JH, Liao Y, Tao H, Green D, Pearce WH, Schneider JR, McPherson D, Laing ST, McCarthy WJ, Shroff A, Criqui MH. Treadmill Exercise and Resistance Training in Patients With Peripheral Arterial Disease With and Without Intermittent Claudication A Randomized Controlled Trial. JAMA. 2009 Jan 14;301(2):165–174. [PMC free article] [PubMed]